Through this agreement, Lupin will introduce two new formulations, a fixed-dose combination of Rifapentine + Isoniazid and Rifapentine 300 mg standalone tablets, at an affordable price
The certification will open new avenues for our flagship brand “Dr Trust”, enabling them to export these devices to many more countries
The company increases its efficiency and is able to face the growing demand for its services.
Campaign to celebrate World Mental Health Day theme "Mental Health in an Unequal World"
Acquisition brings leading sickle cell disease portfolio and pipeline to Pfizer with potential to address critical needs in an underserved patient community
The reduction in force will result in financial savings of approximately $50 million annually beginning in 2023
This clinical study will inform operational logistics and use of AV7909 should an anthrax emergency occur.
Glenmark is the first company in India to launch Thiazolidinedione Lobeglitazone (0.5 mg).
DSCO has requested WHO to share at the earliest with CDSCO the report on establishment of causal relation to death with the medical products in question etc.
Dr. Fesharaki most recently served as the Chief Scientific Officer and Global Head of R&D for Hikma Pharmaceuticals.
Subscribe To Our Newsletter & Stay Updated
